Your browser doesn't support javascript.
loading
Myeloma natural killer cells are exhausted and have impaired regulation of activation.
D'Souza, Criselle; Keam, Simon P; Yeang, Han Xian Aw; Neeson, Michael; Richardson, Kelden; Hsu, Andy K; Canfield, Rachael; Bezman, Natalie; Robbins, Michael; Quach, Hang; Ritchie, David S; Harrison, Simon J; Trapani, Joseph A; Prince, H Miles; Beavis, Paul A; Darcy, Phillip K; Neeson, Paul J.
Afiliação
  • D'Souza C; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne. criselle.dsouza@petermac.org.
  • Keam SP; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne.
  • Yeang HXA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
  • Neeson M; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
  • Richardson K; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
  • Hsu AK; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
  • Canfield R; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
  • Bezman N; Oncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA, USA. Current: Arsenal Bio, San Francisco, CA 94080.
  • Robbins M; Translational Medicine, Bristol-Myers Squibb, Cambridge, MA, USA, (current: io904 LLC).
  • Quach H; Department of Hematology, St Vincent's Hospital, Melbourne, Australia; Faculty of Medicine, University of Melbourne.
  • Ritchie DS; Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Faculty of Medicine, University of Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
  • Harrison SJ; Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
  • Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne.
  • Prince HM; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
  • Beavis PA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne.
  • Darcy PK; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne.
  • Neeson PJ; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne. paul.neeson@petermac.org.
Haematologica ; 106(9): 2522-2526, 2021 09 01.
Article em En | MEDLINE | ID: mdl-34011135
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2021 Tipo de documento: Article